Navigation Links
EntreMed's ENMD-2076 Active in Solid and Hematological Cancers
Date:11/16/2009

nts for ovarian cancer patients who have failed current standard of care.

These clinical data combined with the known mechanisms of ENMD-2076, including its antiangiogenic properties and activity against several targets important in the pathogenesis of ovarian cancer, support the selection of this indication to begin the Phase 2 program. EntreMed has received orphan drug designation for the use of ENMD-2076 in ovarian cancer patients and the Phase 2 study is expected to commence in the second quarter of 2010.

EntreMed Vice President and Chief Medical Officer, Carolyn F. Sidor, MD, MBA commented, "Although the leukemia study remains ongoing, data so far are very encouraging. ENMD-2076 alone was able to induce remission in an acute leukemia patient with a Flt-3 mutation. Additionally, some patients without this mutation achieved significant hematological improvements with reductions in blast percentages and/or the need for transfusions. It is possible that some of ENMD-2076's targets other than Flt-3 play a role in its activity and this is under active investigation. We are expanding the AML study to include additional patients that may benefit from ENMD-2076 therapy."

Dr. Sidor continued, "We are pleased to have selected a Phase 2 indication as it represents an important next step in advancing our clinical program for ENMD-2076. As reported earlier this year, ovarian cancer patients participating in the Phase 1 study in solid tumors were among those who demonstrated marked clinical benefit from ENMD-2076 administered orally as a single agent. We anticipate commencement of a Phase 2 study that will further define the activity of ENMD-2076 in relapsed or refractory ovarian cancer patients. We will continue to determine other potential uses for ENMD-2076 in cancer therapy by evaluating the results from our solid tumor Phase 1 study. Clinical data presented to date support the compound's activity in a variety of solid and hemat
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
2. EntreMed Presents Initial Clinical Results for ENMD-2076
3. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
4. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
5. Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National Active Lifestyle Skincare Destinations
6. Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds
7. Accurays Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers
8. MolSofts New Technology Brings Online Publications to Life in Fully Interactive 3D
9. Medcos 2010 Medicare Prescription Drug Plan Helps People Take an Active Part in Lowering Prescription Costs
10. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
11. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013 Valeant Pharmaceuticals ... ) (TSX: VRX) today announced the ... its 2013 annual meeting of shareholders ... vote for the election of directors ... Farmer235,731,9341,964,748Robert A. Ingram233,865,8763,830,806Theo Melas-Kyriazi237,081,508615,174G. Mason Morfit235,623,2832,073,399J. ...
(Date:5/21/2013)... EAST TAUNTON, Massachusetts , 21 de mayo de ... Synergy, Inc. ("OSI"), cuyas compañías filiales incluyen OMNIlife ... a dos directores experimentados para su junta. Guy Mayer, ... junta directiva y David Johnson ... unirá como director. Antes de unirse ...
(Date:5/21/2013)... and PHILADELPHIA , May 21, 2013 ... its new corporate image and impressive new product developments at ... . "After ten years of unerring focus on product ... felt the need to mark the occasion," said founding director ... we have some interesting developments of benefit to our clients ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 3
(Date:5/22/2013)... from a large observational study reported at ... superior to heparin in the absence of ... patients with non-ST segment elevation acute coronary ... European and US NSTE-ACS guidelines currently recommend ... heparin plus GP IIb/IIIa receptor inhibitors in ...
(Date:5/22/2013)... MA (PRWEB) May 22, 2013 In ... hit the country’s fields and courts with donated ... Sports, a Massachusetts-based nonprofit dedicated to partnering with manufacturers ... is celebrating the donation of $8.8 million in sports ... more than a half-million kids outfitted for physical activity. ...
(Date:5/22/2013)... Following the success of last year’s ... Fit Body Boot Camp Kincardine has announced it will ... starting on June 3rd at its Kincardine fitness ... Kincardine, Ontario.     , Fit Body Boot Camp’s 1,000 lb. ... community residents to lose a total of 1,000 pounds ...
(Date:5/22/2013)... Jersey City, NJ (PRWEB) May 22, 2013 ... governance, compliance, and management solutions for social enterprise ... Partners, LLC, a consulting firm based in Chicago, ... to integrate their products and provide best-in-class solutions ... productivity and improve collaboration. , AvePoint’s DocAve ...
(Date:5/22/2013)... adherence to appropriate medication therapy has been shown to ... 125,000 deaths in the U.S. every year are attributed ... estimated that between 33% and 69% of all medication-related ... a reality that costs the American health-care system approximately ... degree of medication non-adherence — and the consequences therefrom ...
Breaking Medicine News(10 mins):Health News:Registry questions superiority of bivalirudin over heparin 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 3Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 2Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 3Health News:Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance 2
... 25 Former NFL player and Dallas Cowboy,Jason Kaiser ... graduation ceremony. Kaiser earned the title of,valedictorian with a ... people in,this school and in my class especially," he ... Before enrolling in Parker College, Kaiser played professional football,for ...
... protein levels could key future treatments for Alzheimer,s , , ... finds that where protein-destroying machines reside in the brain,s ... a finding that may play a role in future ... Wake Forest University School of Medicine researchers studying mice ...
... his left eyebrow was possibly skin cancer , , FRIDAY, ... during his lifetime, historians have gone to great lengths ... of Franklin Delano Roosevelt, the 32nd president of the ... and heart disease is now well-documented. But a new ...
... QLT Inc. (NASDAQ: QLTI;,TSX: QLT) today reported financial results ... otherwise, all amounts are in U.S. dollars,and in accordance ... 2008, we were pleased to report the U.S. Food,and ... blood,monitoring from the Aczone(TM) label," said Bob Butchofsky, President ...
... Inc., (a wholly owned,subsidiary of Mentice AB), a ... the field of medicine, has recently appointed,Jeff Sirek ... Clinical,Applications Manager for the Americas., Jeff Sirek ... years with GE Healthcare in its Cardiovascular Ultrasound,Division ...
... Solutions, Inc. announced,today the addition of Dr. Marc ... serve as Vice President of Research and Development ... of spine,system/orthopedic development experience, most recently having directed,development ... Marc to Facet Solutions bolsters an already great,team, ...
Cached Medicine News:Health News:Former Dallas Cowboy Honored as Parker College of Chiropractic Top 2008 Graduate 2Health News:Former Dallas Cowboy Honored as Parker College of Chiropractic Top 2008 Graduate 3Health News:When It Comes to Memory, It's All About Location 2Health News:FDR Might Have Had Melanoma 2Health News:FDR Might Have Had Melanoma 3Health News:FDR Might Have Had Melanoma 4Health News:QLT announces first quarter results for 2008 2Health News:QLT announces first quarter results for 2008 3Health News:QLT announces first quarter results for 2008 4Health News:QLT announces first quarter results for 2008 5Health News:QLT announces first quarter results for 2008 6Health News:QLT announces first quarter results for 2008 7Health News:QLT announces first quarter results for 2008 8Health News:QLT announces first quarter results for 2008 9Health News:QLT announces first quarter results for 2008 10Health News:QLT announces first quarter results for 2008 11Health News:QLT announces first quarter results for 2008 12Health News:QLT announces first quarter results for 2008 13Health News:QLT announces first quarter results for 2008 14Health News:Mentice, Inc. Expands Its North American Sales and Clinical Presence With the Hiring of Jeff Sirek as Director of Educational Sales-East and Sue Landsman as Clinical Applications Manager for the Americas. 2Health News:Facet Solutions, Inc. Expands Executive Management Team 2
... is a fully automatic fluorescence photomicrography system ... of even the most difficult specimens. Designed ... PM20 system provide solution to the complex ... their automatic exposure control, the system utilizes ...
... in the PM series is designed ... for routine brightfield observation, both in ... Remarkably economical in,price, it offers a ... which meet the needs of todays ...
... camera system for high resolution photomicrography. The ... of the highest color fidelity, resolution and ... expect perfect images due to many unique ... innovative readout modes. The Leica DFC480 is ...
This compact photomicrographic system assures simple operation to achieve the exposure accuracy required for sophisticated photomicrography in most research and clinical environments....
Medicine Products: